Lumira, Difference Capital back Aurinia-Isotechnika merger with $6 mln investment

Edmonton, Alberta-based Isotechnika Pharma Inc (TSX: ISA) has completed its previously announced merger with Aurinia Pharmaceuticals Inc. The new company, which is focused on pharmaceuticals targeted to the global nephrology market, will conduct business as Aurinia Pharmaceuticals. The merger was facilitated by a $6 million investment by Canadian venture capital firm Lumira Capital, merchant bank Difference Capital, ILJIN Life Science Co. Ltd., and other investors. Benjamin Rovinski, managing director of Lumira, has joined Aurinia's board of directors.

CanadaNorth AmericaBriefs